Target type: biologicalprocess
The chemical reactions and pathways resulting in the formation of xanthine, 2,6-dihydroxypurine, a purine formed in the metabolic breakdown of guanine but not present in nucleic acids. [GOC:go_curators]
The xanthine biosynthetic process is a crucial metabolic pathway that produces xanthine, a key purine base found in various biological molecules. This process involves a series of enzymatic reactions that convert hypoxanthine, a precursor purine, into xanthine. The pathway begins with the enzyme xanthine dehydrogenase, which catalyzes the oxidation of hypoxanthine to xanthine. This oxidation reaction involves the transfer of two electrons and two protons from hypoxanthine to the enzyme, resulting in the formation of xanthine. The process is further regulated by the availability of molecular oxygen, which serves as the electron acceptor in the reaction. Xanthine dehydrogenase is a complex enzyme with multiple cofactors, including molybdenum, iron-sulfur clusters, and flavin adenine dinucleotide (FAD). These cofactors are essential for the enzyme's catalytic activity and play a crucial role in the electron transfer process. The xanthine biosynthetic process is tightly regulated to ensure adequate levels of xanthine for purine metabolism. This regulation involves feedback mechanisms, where high levels of xanthine inhibit the activity of xanthine dehydrogenase, preventing excessive accumulation of xanthine. Furthermore, the process is influenced by factors such as dietary intake of purines and the activity of other metabolic pathways, such as the urea cycle. The xanthine biosynthetic process plays a critical role in various biological functions. Xanthine serves as a precursor for uric acid, a major end product of purine metabolism, and its synthesis is essential for the proper functioning of purine salvage pathways. Disruptions in the xanthine biosynthetic process can lead to several disorders, including xanthinuria, a rare metabolic disorder characterized by the accumulation of xanthine in the body. The xanthine biosynthetic process is a complex and tightly regulated pathway that plays a vital role in purine metabolism and cellular function.'
"
Protein | Definition | Taxonomy |
---|---|---|
Adenosine deaminase | An adenosine deaminase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00813] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
9-(2-hydroxy-3-nonyl)adenine | 9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase | ||
coformycin | coformycins | EC 3.5.4.4 (adenosine deaminase) inhibitor | |
adenosine | quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
nebularine | nebularine : A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage. nebularine: structure | purine ribonucleoside; purines D-ribonucleoside | fungal metabolite |
9-(2-hydroxy-3-nonyl)adenine | (2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase. | EHNA | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor |
9-(2-hydroxy-3-nonyl)adenine | (2S,3R)-EHNA : EHNA of absolute configuration 2S,3R. | EHNA | |
1-deazaadenosine | 1-deazaadenosine: inhibits nucleic acid & protein synthesis; structure given in first source | ||
pentostatin | pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia. Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | coformycins | antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor |
8-azanebularine | 8-azanebularine: structure in first source | ||
msh, 4-nle-7-phe-alpha- | polypeptide | dermatologic drug |